RIGImmune

Focus: RIGImmune is a newly founded (2024) biotechnology company headquartered in Farmington, CT specializing in RNA immunotherapeutics focused on gene therapy applications. As a public-stage company, it represents an early-stage player in the RNA therapeutic space.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About RIGImmune

AI assessmentNot Hiring

No open roles listed right now. Follow RIGImmune to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RIG-101

Healthy Adult Participants

Phase 1/2

Clinical Trials (1)

NCT07488897RIG 101 Trial in Healthy Adults and Adults With Asthma

Phase 1/2

Help build intelligence for RIGImmune

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly public company in the high-growth RNA immunotherapeutics space with potential for significant equity upside
Focus on gene therapy positions you at the intersection of cutting-edge molecular biology and transformative treatment modalities
Connecticut location provides access to Northeast biotech talent hub without the cost-of-living pressures of Boston or San Francisco

Watch Out For

Zero clinical trials currently active—no near-term clinical or regulatory catalysts to drive visibility or validation of technology platform
No disclosed funded pipeline, products, or hiring activity visible, raising questions about operational stage, capital adequacy, and near-term growth trajectory
Extreme early-stage risk: company founded in 2024 with no publicized management team, financial data, or proof-of-concept publications

Generated by Claude from RIGImmune's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 1 clinical trial

Top TAs: Respiratory

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Respiratory

1 pipeline

Marketed

Pipeline